Specialty Rx Is Driving Drug Trend Among CVS Caremark Clients
This article was originally published in The Pink Sheet Daily
CVS Caremark’s annual Insights report says that while use of generics for small molecule drugs restrained spending growth, an 18.1% surge in spending on specialty medications by its commercial clients pushed the overall drug trend into positive territory in 2012.
You may also be interested in...
Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.
More than a dozen new molecular entities launched for the treatment of cancer in 2012, advancing care for seriously ill people, but many carry price tags of $100,000 per year or more for treatment, escalating debate over cost of care and how best to direct limited healthcare resources.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.